Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576685 | 1.00 | CTSS (0.56) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL30051055 | 1.00 | CTSS (0.56) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL15856094 | 0.90 | CTSS (0.55) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL15856124 | 0.90 | CTSS (0.55) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL3355326 | 0.90 | CTSS (0.64) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL85543 | 0.90 | CTSS (0.64) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL22404737 | 0.90 | CTSS (0.64) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL12643835 | 0.89 | CTSS (0.52) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL2352336 | 0.89 | KLK5 (0.59) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL6491302 | 0.89 | KLK5 (0.59) | CTSSCTSKCTSBACECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2019075259-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | CTSS 468/4885CTSK 1005/4885CTSB 803/4885 |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | CTSS 1204/4885CTSK 1544/4885CTSB 1041/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSS 640/4885CTSK 1101/4885CTSB 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.